Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016

被引:6
作者
Wang, Weigang [1 ,2 ]
Xu, Xiaoqin [1 ,2 ]
Tian, Baoguo [1 ,2 ]
Wang, Yan [1 ,2 ]
Du, Lili [1 ,2 ]
Sun, Ting [1 ,2 ]
Shi, Yanchun [1 ,2 ]
Zhao, Xianwen [1 ,2 ]
Jia, Yali [3 ]
Xi, Yanfeng [4 ]
Jing, Jiexian [1 ,2 ]
机构
[1] Shanxi Canc Hosp, Dept Etiol, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Canc Hosp, Tumor Marker Lab, Taiyuan, Shanxi, Peoples R China
[3] Shanxi Canc Hosp, Dept Prevent Hlth Care, Taiyuan, Shanxi, Peoples R China
[4] Shanxi Canc Hosp, Dept Pathol, Taiyuan, Shanxi, Peoples R China
关键词
PROGNOSTIC-FACTORS; CARCINOMA; MEN; EXPERIENCES; SURVIVAL;
D O I
10.1136/jim-2018-000823
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study aims to understand the clinical features, treatment, and prognosis of patients with male breast cancer (MBC) in Shanxi province of China from 2007 to 2016. Data for 77 patients with MBC were collected for analysis. Immunohistochemistry, pathological results, and other data such as demographic characteristics (age, marital status, smoking history, drinking history, and family history of cancer) as well as clinical data were investigated by retrieving information from the patients' medical records. A total of 12,404 patients were diagnosed with breast cancer between 2007 and 2016, and 77 were patients with MBC among them. The median diagnosis age of patients with MBC was 62 years (range, 24- 84 years). The most common complaint was a painless lump in the breast, accounting for 68.8% of the patients, and the main pathological type in MBC was infiltrating ductal carcinoma (66.2%). In terms of hormone receptors, 80.5% (62/77) of patients with MBC were estrogen receptor positive, 75.3% (58/77) of patients were progesterone receptor positive, and only 6.5% (5/77) of patients were HER2 overexpressing. The multivariant Cox proportional hazards regression analysis showed that M stage is an independent prognostic factor (p=0.018, HR=18.791, 95% CI 1.663 to 212.6). The epidemiological and clinical features of Chinese MBC are similar to that of other countries. As the Chinese public have limited knowledge of MBC, it is necessary to increase awareness among them about it. Further research with a large sample size is required for better understanding of the risks associated with MBC.
引用
收藏
页码:700 / 706
页数:7
相关论文
共 39 条
  • [1] TAMOXIFEN IN ADVANCED MALE BREAST-CANCER
    AISNER, J
    ROSS, DD
    WIERNIK, PH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (04) : 480 - 481
  • [2] Is male breast cancer similar or different than female breast cancer?
    Anderson, WF
    Althuis, MD
    Brinton, LA
    Devesa, SS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) : 77 - 86
  • [3] Male breast cancer: A report of 127 cases at a Moroccan institution
    Bourhafour M.
    Belbaraka R.
    Souadka A.
    M'Rabti H.
    Tijami F.
    Errihani H.
    [J]. BMC Research Notes, 4 (1)
  • [4] Prospective Evaluation of Risk Factors for Male Breast Cancer
    Brinton, Louise A.
    Richesson, Douglas A.
    Gierach, Gretchen L.
    Lacey, James V., Jr.
    Park, Yikyung
    Hollenbeck, Albert R.
    Schatzkin, Arthur
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (20): : 1477 - U9
  • [5] Male breast cancer: Clinico-pathological features, immunocytochemical characteristics and prognosis
    Bruce, DM
    Heys, SD
    Payne, S
    Miller, ID
    Eremin, O
    [J]. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1996, 22 (01): : 42 - 46
  • [6] Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
    Cardoso, F.
    Bartlett, J. M. S.
    Slaets, L.
    van Deurzen, C. H. M.
    van Leeuwen-Stok, E.
    Porter, P.
    Linderholm, B.
    Hedenfalk, I.
    Schroder, C.
    Martens, J.
    Bayani, J.
    van Asperen, C.
    Murray, M.
    Hudis, C.
    Middleton, L.
    Vermeij, J.
    Punie, K.
    Fraser, J.
    Nowaczyk, M.
    Rubio, I. T.
    Aebi, S.
    Kelly, C.
    Ruddy, K. J.
    Winer, E.
    Nilsson, C.
    Dal Lago, L.
    Korde, L.
    Benstead, K.
    Bogler, O.
    Goulioti, T.
    Peric, A.
    Litiere, S.
    Aalders, K. C.
    Poncet, C.
    Tryfonidis, K.
    Giordano, S. H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (02) : 405 - 417
  • [7] Incidence and mortality of breast cancer in China, 2008
    Chen, Wan-qing
    Zheng, Rong-shou
    Zeng, Hong-mei
    Zhang, Si-wei
    Li, Guang-lin
    Wu, Liang-you
    He, Jie
    [J]. THORACIC CANCER, 2013, 4 (01) : 59 - 65
  • [8] El Omari-Alaoui H, 2002, Cancer Radiother, V6, P349, DOI 10.1016/S1278-3218(02)00250-0
  • [9] Male breast cancer
    Fentiman, IS
    Fourquet, A
    Hartobagyi, GN
    [J]. LANCET, 2006, 367 (9510) : 595 - 604
  • [10] The Epidemiology of Male Breast Cancer
    Ferzoco, Raina M.
    Ruddy, Kathryn J.
    [J]. CURRENT ONCOLOGY REPORTS, 2016, 18 (01) : 1 - 6